An interventional study of Phycocyanin and Maltodextrin in Intrahepatic Cholangiocarcinoma (Icc) and Liver Injury, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 229 studies in Cholangiocarcinoma with a site in China — 113 open to participants now, 124 under way, 12 of them phase 3. Cholangiocarcinoma · China.
Among the 229 studies in Cholangiocarcinoma with a site in China, this one is the 139th largest by planned enrollment of the 190 interventional ones that give a count, is one of 21 that started in 2026, is one of 33 with no phase, reaches primary completion later than 112 of the 123 other live ones, and was the 221st registered.
824 studies on the registry are indexed under Cholangiocarcinoma; 287 are open to participants now.
Browse Cholangiocarcinoma studies →113 of the 229 studies in Cholangiocarcinoma with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75
Virogin Biotech Ltd. · Sites in China
Ages 18–75
Peking University Third Hospital · Sites in China
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
Lianghe Lu · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
229 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 117 · Phase 3 25 · Phase 4 3
First in 2006; this study’s year is marked. 21 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 50 across 623 interventional studies indexed under Cholangiocarcinoma.
Median enrollment 51 across the 190 interventional studies, 150 across the 39 observational. Of the 51 that completed or were terminated, 7 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 229 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.
Second Affiliated Hospital, Zhejiang University, School of Medicine has 1 study filed under Cholangiocarcinoma — fewer than ten, so there is no comparison to draw.
27 of the studies in Cholangiocarcinoma with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05823311Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityLenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma | 2026-12-31 |
| NCT05342194Phase 3Shanghai Junshi Bioscience Co., Ltd.Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study | 2027-05-31 |
| NCT05727176Taiho Oncology, Inc.Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | 2026-12 |
| NCT07359586Zhejiang UniversityLaryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia | 2026-12-25 |
| NCT06664021Anhui Provincial HospitalExploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma | 2026-12-30 |
Add all 27 to your calendar (.ics) → With an account.
Among the 229 studies in Cholangiocarcinoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to find out whether phycocyanin, a natural protein from spirulina, can help protect the liver and support recovery in adults having part of their liver removed. The study will also look at whether phycocyanin is safe to take.The main questions are:
Does phycocyanin reduce liver injury after surgery? Does it help the liver grow back and recover? What side effects or medical problems happen while taking it?
Researchers will compare phycocyanin with a placebo, which looks similar but does not contain phycocyanin. About 30 people will take part. Each person will be randomly placed into one of the two groups, and neither the participants nor the researchers will know which treatment each person receives during the study.
Participants will:
Take 1.5 grams of phycocyanin or placebo every day for 3 weeks before surgery and 3 weeks after surgery Receive the usual care for liver surgery Give blood and stool samples before and after treatment Allow researchers to study a small piece of liver tissue removed during surgery Return for follow-up for up to 90 days after surgery
The samples will be used to check liver function, inflammation, gut bacteria, and changes linked to liver healing. Possible side effects include an allergic reaction or stomach discomfort. The study has been approved by an ethics committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take 1.5 grams of phycocyanin by mouth once a day for 3 weeks before surgery and 3 weeks after surgery. They will also receive the usual medical care for partial liver removal surgery.
Dietary Supplement: Phycocyanin
Participants will take 1.5 grams of maltodextrin placebo by mouth once a day for 3 weeks before surgery and 3 weeks after surgery. The placebo does not contain phycocyanin. Participants will also receive the usual medical care for partial liver removal surgery.
Dietary Supplement: Maltodextrin
Participants will take 1.5 grams of phycocyanin by mouth once daily for 3 weeks before partial hepatectomy and for 3 weeks after surgery. Phycocyanin is a natural protein from spirulina.
Participants will take 1.5 grams of maltodextrin placebo by mouth once daily for 3 weeks before partial hepatectomy and for 3 weeks after surgery. The placebo does not contain phycocyanin.
Change in Serum Aspartate Aminotransferase (AST) Level
Time frame: Baseline and Week 3 after surgery
Change in Serum Alanine Aminotransferase (ALT) Level
Time frame: Baseline and Week 3 after surgery
Change in Serum Total Bilirubin (TBIL) Level
Time frame: Baseline and Week 3 after surgery
Change in Blood Inflammatory Marker Levels
Time frame: Baseline and Week 3 after surgery
Liver Cell Proliferation Assessed by Ki-67 Expression
Time frame: Baseline and Week 3 after surgery
Liver Cell Proliferation Assessed by PCNA Expression
Time frame: Baseline and Week 3 after surgery
Incidence of Treatment-Emergent Adverse Events
Time frame: through study completion, an average of 1 year
Started Jun 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.
Of 66 non-industry interventional studies with no phase under Cholangiocarcinoma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 28. This study's planned 35 months is below that.
Counting every sponsor, half of 67 studies reached it within 43 months; a quarter within 28.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, Zhejiang University, School of Medicine →